靶向放射性核素治疗联合免疫检查点抑制在动物肿瘤模型中的疗效:系统综述与Meta分析
该系统综述与Meta分析纳入31项动物肿瘤模型研究,评估靶向放射性核素治疗(TRT)联合免疫检查点抑制(ICI)的疗效。所有Meta分析均显示联合治疗较未治疗、TRT单药和ICI单药显著改善生存与肿瘤生长,但研究间异质性高(I²=76.7-98.2%)。作者认为现有文献尚不足以确定TRT肿瘤吸收剂量和ICI类型等最佳治疗参数。
要点
- 联合治疗较未治疗、TRT单药和ICI单药均显著改善动物模型生存与肿瘤生长。
- 研究间异质性高(I²=76.7-98.2%),ICI作用机制可能是疗效调节因素。
- 现有文献尚不足以确定TRT肿瘤吸收剂量和ICI类型等最佳治疗参数。
核心结论
- 该系统综述强调TRT/ICI联合治疗的治疗潜力,展示临床前概念验证并支持进一步在临床试验中评估。
- 当前文献仍不足以确定TRT肿瘤吸收剂量和ICI类型等最佳治疗参数以用于临床转化。
- 需采用改进的报告标准进一步研究,系统评估此类参数的影响以实现稳健比较。
研究设计与样本
- 系统检索MEDLINE-PubMed和Embase-OVID,评估研究特征与偏倚风险。
- 共纳入31项动物肿瘤模型研究。
- 结局参数包括归一化肿瘤生长曲线下面积和限制性平均生存时间,在随机效应Meta分析中分析联合治疗与未治疗及单药组间的比值。
- 预设亚组分析探索疗效的潜在调节因素。
主要发现
- 所有Meta分析均显示高研究间异质性(I²=76.7-98.2%)。
- 亚组分析显示ICI的具体作用机制可能是治疗疗效的潜在调节因素。
- 研究特征如动物性别和年龄、癌症类型、TRT靶点和放射性核素在各研究间差异很大。
关键数值与推荐
- 所有Meta分析异质性I²=76.7-98.2%。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 研究特征如动物性别和年龄、癌症类型、TRT靶点和放射性核素在各研究间差异很大。
- 由于报告质量差,纳入研究的质量并非总能评估。
- 所有Meta分析均显示高研究间异质性(I²=76.7-98.2%)。
- 当前文献仍不足以确定TRT肿瘤吸收剂量和ICI类型等最佳治疗参数以用于临床转化。
- 需采用改进的报告标准进一步研究,系统评估此类参数的影响以实现稳健比较。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Given radiation's immunomodulatory effects and the complementary anti-cancer mechanisms of targeted radionuclide therapy (TRT) and immune checkpoint inhibition (ICI), their combination holds promise as a cancer treatment. This systematic review and meta-analysis summarize the literature on the therapeutic efficacy of combined TRT/ICI in animal tumour models. METHODS: A systematic search in MEDLINE-PubMed and Embase-OVID was performed. Study characteristics and risk of bias were assessed. Outcome parameters included normalized area under the tumour growth curve and restricted mean survival time, of which ratios between combined treatment and untreated and monotherapy groups were analysed in a random-effects meta-analyses. Predefined subgroup analyses explored potential moderators of treatment efficacy. RESULTS: In total, 31 studies were included. Study characteristics such as animal sex and age, cancer type, TRT target, and radionuclides, varied considerably across studies. The quality of the included studies could not always be assessed due to poor reporting. All meta-analyses indicated significantly improved survival and tumour growth of combination treatment over untreated, TRT and ICI monotherapy controls (RMST ratio 1.96 [1.72-2.23], 1.44 [ 1.34-1.55], 1.54 [1.38-1.72], and nAUC ratio 0.32 [0.25-0.42], 0.49 [0.41-0.59], 0.41 [0.31-0.55], respectively), with high between-study heterogeneity (I2 = 76.7-98.2%). The specific mode of action of ICI emerged as a potential moderator of treatment efficacy in subgroup analyses. CONCLUSION: This systematic review highlights the therapeutic potential of combined TRT/ICI treatment, demonstrating preclinical proof-of-concept and supporting its further evaluation in clinical trials. However, the current literature remains insufficient to determine optimal treatment parameters like TRT tumour-absorbed dose and ICI type for clinical translation. Further research with improved reporting standards should systematically evaluate the impact of such parameters to enable robust comparisons.
引用
- Kleinendorst SC, Hooijmans CR, Muselaers S, et al. Efficacy of combined targeted radionuclide therapy and immune checkpoint Inhibition in animal tumour models: a systematic review and meta-analysis of the literature. Eur J Nucl Med Mol Imaging. 2025. PMID: 40281282. doi:10.1007/s00259-025-07293-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。